The Food and Drug Administration is investigating a possible link between the use of the asthma medication Singulair.
Merck & Co, Inc. has already updated the prescribing and patient info for the medication to include depression, suicidality (suicidal thinking) and anxiousness.
The FDA has also received post-marketing reports from patients and patients’ family members of rapid mood changes, suicidal thinking and suicide.
Other drugs recently in the news for possible links to suicide include several anti-depressants and the stop-smoking drug Chantix.
Recent Comments